Preview

Российский кардиологический журнал

Расширенный поиск

НУЖЕН ЛИ КОНТРОЛЬ ЧСС ПРИ ЛЕЧЕНИИ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ?

https://doi.org/10.15829/1560-4071-2014-1-107-110

Аннотация

В данном литературном обзоре говорится о значении контроля за частотой сердечных сокращений при выборе и назначении адекватной гипотензивной терапии.

Об авторе

С. В. Недогода
Волгоградский государственный медицинский университет, Волгоград, Россия
Россия
профессор, заведующий кафедрой терапии и эндокринологии


Список литературы

1. S halnova SA, Deev AD, Oganov RG. Factors influencing cardiovascular mortality in russian population. Cardiovascular Therapy and Prevention, 2005, 4 (1): 4–9. Russian (Шальнова С . А ., Деев А . Д., Оганов Р. Г. Факторы, влияющие на смертность от сердечно-сосудистых заболеваний в российской популяции. Кардиоваскулярная терапия и профилактика, 2005; 4 (1): 4–9).

2. Empana JP, et al. Paris Prospective Study III: a study of novel heart rate parameters, baroreflex sensitivity and risk of sudden death. European journal of epidemiology 2011; 26 (11):887–92.

3. Palatini P, et al. Resting heart rate as a predictor of body weight gain in the early stage of hypertension. Obesity 2011; 19 (3):618–23.

4. Tardif JC, et al. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. European heart journal 2005; 26 (23):2529–36.

5. S alles GF, Cardoso CRL, Fonseca LL, et al. Prognostic Significance of Baseline Heart Rate and Its Interaction With Beta-Blocker Use in Resistant Hypertension: A Cohort Study. Am. J. H ypertens. 2013; 26:218–26.

6. Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. H ypertens. 2007; 25:1105–87.

7. Palatini P, Mos L, Santonastaso M, et al. Resting heart rate as a predictor of body weight gain in the early stage of hypertension. Obesity. 2011; 19:618–23.

8. Shigetoh Y, et al. Higher heart rate may predispose to obesity and diabetes mellitus: 20-year prospective study in a general population. American journal of hypertension. 2008; 22 (2):151–5.

9. Custodis F, Shirmer SH, Baumhakel M, et al. Vascular pathophysiology in response to increased heart rate. J. Am. Coll. Cardiol. 2010; 56:1973–83.

10. Diaz A, Bourassa MG, Guertin M–C, et al. Long-term prognostic value of resting heart rate in patients with suspected of proven coronary artery disease. Eur. Heart J. 2005; 26:967–74.

11. Reule S, Drawz PE. Heart Rate and Blood Pressure: Any Possible Implications for Management of Hypertension? Current hypertension reports. 2012; 14 (6):478–84.

12. Kobalava ZhD. Clinical and prognostic significance of elevated heart rate and its correction in arterial hypertension. RMJ 2013: 27:1334–42. Russian (Кобалава Ж. Д. Клинико-прогностическое значение повышенной частоты сердечных сокращений и ее коррекции при артериальной гипертонии. РМЖ 2013: 27:1334–42).

13. King DE, Everett CJ, Mainous AG, et al. Long-term prognostic value of resting heart rate in subjects with prehypertension. Am. J. H ypertens. 2006; 19:796–800.

14. Cooney MT, et al. Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women. American heart journal. 2010; 159 (4):612–9. e3.

15. Inoue T, Iseki K, Iseki C, et al. Higher heart rate predicts the risk of developing hypertension in a normotensive screened cohort. Circ. J. 2007; 71:1755–60.

16. Cuspidi C, et al. Ambulatory heart rate and target organ damage in never-treated essential hypertensives. Journal of human hypertension. 2007; 22 (2):89–95.

17. García-García Á, et al. Office and 24-hour heart rate and target organ damage in hypertensive patients. BMC Cardiovascular Disorders. 2012; 12 (1):19.

18. Hartaigh BO, Bosch JA, Carroll D, et al. Evidence of a synergistic association between heart rate, inflammation, and cardiovascular mortality in patients undergoing coronary angiography. Eur Heart J. 2013;34:932–41.

19. Facila L, Pallares V, Peset A, et al. Twenty-four-hour ambulatory heart rate and organ damage in primary hypertension. Blood. Press. 2010; 19:104–9.

20. Júnior IFF, et al. Resting heart rate as a predictor of metabolic dysfunctions in obese children and adolescents. BMC pediatrics. 2012; 12 (1):5.

21. Rogowski O, et al. Elevated resting heart rate is associated with the metabolic syndrome. Cardiovasc Diabetol. 2009; 8 (55):327–31.

22. Chu CY, et al. Heart Rate Significantly Influences the Relationship between Atrial Fibrillation and Arterial Stiffness. International journal of medical sciences. 2013; 10 (10):1295.

23. Park BJ, et al. Association between resting heart rate and arterial stiffness in Korean adults. Archives of Cardiovascular Diseases. 2010; 103 (4):246–52.

24. Fox K, Borer JS, Camm J, et al. The Heart Rate Working Group. Resting heart rate in cardiovascular disease. J. Am. Coll. Cardiol. 2007; 50:823–30.

25. Giannoglou GD, Chatzizisis YS, Zamboulis C, et al. Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. Int. J. Cardiol. 2008; 126:302–12.

26. Inoue T, Iseki K, Iseki C, et al. Heart rate as a risk factor for developing chronic kidney disease: longitudinal analysis of a screened cohort. Clin. Exp. Nephrol. 2009; 13:487–93.

27. Bohm M, Reil JC, Danchin N, et al. Association of heart rate with microalbuminuria in cardiovascular risk patients: data from I-SEARCH. J. H ypertens. 2008; 26:18–25.

28. Julius S, Palatini P, Kjeldsen S, et al. Tachycardia predicts cardiovascular events in the VALUE trial. American Society of Hypertension 2010 Scientific Meeting; May 1–4, 2010. New York, NY. Abstract LB-OR-01.

29. Palatini P. Role of elevated heart rate in the development of cardiovascular disease in hypertension. Hypertension. 2011; 58 (5):745–50.

30. Borer JS. Heart rate: from risk marker to risk factor in coronary artery disease. Medicographia. 2009; 31:349–55.

31. Poulter NR, et al. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). Journal of the American College of Cardiology. 2009; 54 (13):1154–61.

32. Rambihar S, Gao P, Teo K, et al. Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/TRANSCEND. Circulation. 2010; 122: A12667

33. Kolloch R, Legler UF, Champion A, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the International Verapamil -SR/trandolapril STudy (INVEST). Eur. Heart J. 2008; 29:1327–34.

34. Palatini P. Is there benefit of cardiac slowing drugs in the treatment of hypertensive patients with elevated heart rate? Eur. Heart J. 2008; 29:1218–20.

35. Bramlage P, et al. A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patients. The Journal of Clinical Hypertension. 2010; 12 (9):666–77.

36. Bangalore S, Sawhney S, Messerli FH. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J. Am. Coll. Cardiol. 2008; 52:1482–9.

37. Rogowski O, et al. Heart rate and microinflammation in men: a relevant atherothrombotic link. Heart. 2007; 93 (8):940–4.

38. Mulder P, Barbier S, Chagraoui A, et al. Long-term heart rate reduction induced by the selective If current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation. 2004; 109:1674–9.

39. S aladini F, Benetti E, Mos L, et al. Evolution of parameters of arterial distensibility in a cohort of young-to-middle-age hypertensive subjects. J. H ypertens. 2010; 28: e176.

40. Tomiyama H, Hashimoto H, Tanaka H, et al. baPWV/cfPWV Collaboration Group. Synergistic relationship between changes in the pulse wave velocity and changes in the heart rate in middle-aged Japanese adults: a prospective study. J. H ypertens. 2010; 28:687–94.

41. Kobalava ZhD, Kijakbajev GK, Homitskaya JuV. The Results of the Russia supervisory multicenter non-interventional research ATHENA “AchievemenT of goal resting HEart rate on β-blockers in patients with stable angiNA and hypertension in routine practice”. Kardiologija 2013; 7: 13–23. Russian (Кобалава Ж. Д., Киякбаев Г. К ., Хомицкая Ю. В. Результаты Российского наблюдательного многоцентрового неинтервенционного исследования ATHENA “AchievemenT of goal resting HEart rate on β-blockers in patients with stable angiNA and hypertension in routine practice”. Кардиология 2013; 7:13–23).

42. Kampus P, Serg M, Kals J, et al. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertens. 2011; 57:1122–8.

43. Polonia J, Barbosa L, Silva JA, et al. Different patterns of peripheral versus central blood pressure in hypertensive patients treated with β-blockers either with or without vasodilator properties or with angiotensin receptor blockers. Blood Press. Monit. 2010; 15:235–9.

44. Mahmud A, Feely J. β-Blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am. J. H ypertens. 2008; 21:663–7.

45. S hah NK, Smith SM, Nichols WW, et al. Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: a comparison with atenolol (CENTRAL Study). J. Clin. Hypertens. 2011; 13:917–24.

46. Orlova JaА, Mikhailov GV, Хежева FM, et al. The Influence of the bisoprolol therapy on indices of peripheral and central blood pressure, stiffness of the arteries, diastolic left ventricular function and quality of life in patients with arterial hypertension (study KLJuCh). Serdze 2012; 6:342–50. Russian (Орлова Я . А ., Михайлов Г. В., Хежева Ф. М . и др. Влияние терапии бисопрололом на поКазатели периферического и центрального артериаЛьного давления, жесткость артерий, диастолическуЮ функцию левого желудочка и каЧество жизни у больных артериальной гипертонией (исследование КЛЮЧ). Сердце 2012; 6:342–50).

47. Rana R, Patil A. Efficacy and safety of bisoprolol plus amlodipine fixed dose combination in essential hypertension. Indian Pract 2008; 61: 225–34.


Для цитирования:


Недогода С.В. НУЖЕН ЛИ КОНТРОЛЬ ЧСС ПРИ ЛЕЧЕНИИ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ? Российский кардиологический журнал. 2014;(1):107-110. https://doi.org/10.15829/1560-4071-2014-1-107-110

For citation:


Nedogoda S.V. WHETHER CONTROL OF THE HEAT RATE IN THE TREATMENT OF HYPERTENSION? Russian Journal of Cardiology. 2014;(1):107-110. https://doi.org/10.15829/1560-4071-2014-1-107-110

Просмотров: 204


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1560-4071 (Print)
ISSN 2618-7620 (Online)